Experience

HA TECH

• Australia
• Biotechnology Research
• 1 - 100 Employee

• Managing Director

  • Mar 2019 - Present

  Castle Hill NSW, Australia HA TECH is an Australian based Company, Developing & Delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory Including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company has a diagnostic manufacturing facility at Castle Hill, Sydney, Australia. In the last 3 years… Show more HA TECH is an Australian based Company, Developing & Delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory Including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company has a diagnostic manufacturing facility at Castle Hill, Sydney, Australia. In the last 3 years since 2020, the company has seen rapid growth, with more than 30 diagnostic products in the pipeline and being commercialized. The company exported Australian made TGA approved products to over 25 countries since its inception. With the ability to produce 10 million antigen tests and 40 million RT-PCR tests per month, HA Tech holds the largest diagnostic manufacturing capacity in Australia. HA Tech exported millions of COVID-19 test kits in Europe and Asia during the pandemic, comfortably becoming a winner of the 2022 NSW Premier’s Export Awards. The company is hard at work to setup a multi-use biotechnology product facility and aspires to be the premier Australian company to compete in the international arena by supplying locally made human insulin products. Show less



Memphasys

• Membrane Specialist/ Senior Scientist

  • Apr 2010 - Feb 2019

  Hombush west, NSW, Australia Memphasys Ltd (ASX: MEM) is an Australian publicly listed Bio-technology company that develops/ commercialises innovative separation techniques based on membrane technology. The company was formerly known as ‘NuSep Ltd’ and ‘Gardipore Ltd before that, also sold precast electrophoresis gels. THE KEY PROJECTS THAT WERE DIRECTLY MANAGED: •Long life poly-acrylamide electrophoresis Pre-cast gels (2010-12) The development of the long shelf-life gel product was company’s one of… Show more Memphasys Ltd (ASX: MEM) is an Australian publicly listed Bio-technology company that develops/ commercialises innovative separation techniques based on membrane technology. The company was formerly known as ‘NuSep Ltd’ and ‘Gardipore Ltd before that, also sold precast electrophoresis gels. THE KEY PROJECTS THAT WERE DIRECTLY MANAGED: •Long life poly-acrylamide electrophoresis Pre-cast gels (2010-12) The development of the long shelf-life gel product was company’s one of the key objectives to compete with the major competitor companies: Invitrogen, Bio-Rad. The new gel formulation was invented within six months; the new product was sold globally as NG, NB and NN series of NuSep’s long life gels. A patent was filed on the invention. The gel business was sold to Dycent Biotech (Shanghai). • Poly-acrylamide membranes for Blood Plasma Fractionation application (2012-15). Continuous improvement made in the membrane formulation (with different pore size to separate valuable proteins from blood plasma based on it's size and charge), the manufacturing process and QC to meet the requirements for the company’s PrIME (preparative isolation by membrane electrophoresis) project. Besides the development work, managed adequate production and supply of the membranes to PrIME until PrIME spun-out as a separate company PrIME BIOLOGICS based in Singapore. A patent was filed on the invention. •Novel bio-compatible membrane development for Fertility Medical Device (2016- Feb 2019). The project objective was to develop a biocompatible polymer hydrogel membrane by replacing the toxic monomer ‘acrylamide’ that was used to manufacture the existing membrane used for the sperm separation device. The project was successfully completed with the Chemical Engineering department of the University of Melbourne by replacing the toxic monomer without affecting the membrane functionality. Two patents were filed on the inventions. Show less



University of Greenwich

• United Kingdom
• Higher Education
• 700 & Above Employee

• Post doctoral research fellow

  • Dec 2008 - Nov 2009

  The research involved the manufacture and characterisation of polymeric thin films and studying the uptake and release of active materials/fragrance from the prepared films to be used in the delivery of active materials or fragrance via an oral route.

• Part-time lecturing

  • Feb 2006 - Oct 2009